Response Biomedical Regains Rights to Flu, RSV Tests after Termination of 3M Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Response Biomedical said today that as a result of the termination of a collaboration with 3M and 3M Innovative Properties, it has regained the worldwide rights to Flu A+B and respiratory syncytial virus products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.